VIVAN Therapeutics
VIVAN Therapeutics is a London-based precision oncology company that uses an in vivo fruit fly (Drosophila) avatar platform combined with AI/ML drug matching to deliver personalized cancer treatment recommendations to patients with gastrointestinal, lung, rare, and treatment-resistant cancers, via physician-mediated referrals.
- Company typePrivate
- Founded2018
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2C
- OfferingServices
What VIVAN Therapeutics does
VIVAN Therapeutics (legally My Personal Therapeutics Ltd.) is a London-based precision oncology company that delivers personalized cancer treatment recommendations using an in vivo fruit fly (Drosophila) avatar platform combined with AI/ML-based drug matching. The company operates two core products under a unified workflow: TuMatch, a clinical decision-support software interface, and the Personal Discovery Process (PDP), a comprehensive genomics-based drug screening technology. Under PDP, a patient's entire tumor exome is sequenced, the resulting tumor network (up to 20 cancer-associated mutations) is engineered into up to 500,000 fruit fly avatars, and up to 2,000 FDA/NICE-approved drugs, including non-cancer drugs, are screened to identify effective combination therapy cocktails. Treatment recommendations are delivered as a ranked report within 2-5 days of screening data upload, with the full PDP taking 4-5 months from tumor and blood sequencing. A concierge Second Opinion service extends the offering for patients seeking additional expert review.
VIVAN's primary customer segments are patients with gastrointestinal (colorectal, pancreatic) and lung cancers, patients with rare cancers or tumors of unknown origin, and patients with pre-malignant gut lesions for whom standard protocols have failed or do not exist. The go-to-market model is sales-led and physician-mediated: patients initiate the process via the company's website (Calendly consultation booking) and treatment recommendations are reviewed by the patient's oncologist and tumour board before clinical application. Earned media coverage in New Scientist, Forbes, Wired, and Business Insider, combined with physician referrals, drives demand generation. Pricing is quote-based and not publicly disclosed, structured as multi-year contracts per patient engagement.
The underlying PDP technology was developed at the Icahn School of Medicine at Mount Sinai and is licensed exclusively to My Personal Therapeutics Ltd. VIVAN has secured strategic partnerships with Mt. Sinai and, as of November 2025, with the UK Medical Research Council (MRC) Laboratory of Medical Sciences to extend the platform into metabolic-oncology research on KRAS mutations, diabetes, and diet. The company has raised approximately $5.3M across disclosed rounds (SFC Capital 2019, Reflect Ventures and VOYAGERS Health-Tech Fund 2021, European Innovation Council 2022) plus additional investment from the Longevity Investor Network in 2024 and 2025.
VIVAN Therapeutics firmographics
Firmographics- Name
- VIVAN Therapeutics
- Legal name
- My Personal Therapeutics Ltd.
- Website
- https://vivantx.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- VIVAN Therapeutics is a London-based precision oncology company that uses an in vivo fruit fly (Drosophila) avatar platform combined with AI/ML drug matching to deliver personalized cancer treatment recommendations to patients with gastrointestinal, lung, rare, and treatment-resistant cancers, via physician-mediated referrals.
- Ownership category
- akta.pro rank
VIVAN Therapeutics industry classification
Industry- Product category
- Precision Oncology Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where VIVAN Therapeutics is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
VIVAN Therapeutics business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Personalized Cancer Treatment Recommendations (TuMatch/PDP): VIVAN Therapeutics generates revenue by providing personalized drug screening and treatment recommendation reports to patients and their oncologists. The Personal Discovery Process (PDP) takes 4–5 months after tumor and blood sequencing results are available. Treatment recommendations are delivered as reports ranked by efficiency, reviewed by the patient's oncologist and tumour board before clinical application. The company operates as My Personal Therapeutics Ltd. (trading as Vivan Therapeutics).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Personalized drug screening and treatment recommendation (TuMatch) |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
VIVAN Therapeutics product offering
Product offeringCore offering
VIVAN Therapeutics delivers personalized cancer treatment recommendations by sequencing a patient's tumor exome, engineering the identified mutations into fruit fly (Drosophila) avatars, and using robotics and AI/ML to screen up to 2,000 FDA/NICE-approved drugs (including non-cancer drugs) across up to 500,000 avatars. The output is a ranked treatment recommendation report delivered to the patient and their oncologist/tumour board for clinical review.
Product overview
VIVAN Therapeutics offers a unified precision oncology platform centered on TuMatch and the Personal Discovery Process (PDP). TuMatch serves as the clinical decision support software interface, while PDP is the underlying genomic-based drug screening technology that engineers patient-specific tumor mutations into fruit fly avatars for high-throughput drug testing. The platform evaluates up to 2,000 FDA/NICE approved drugs (including non-cancer drugs) using 500,000 fruit fly avatars to identify personalized drug combinations. Concierge services including Second Opinion complement the core offerings for patients seeking additional consultation.
Differentiator
Problem solved
Functional benefit
Brands
- TuMatch: Rapid, personalized clinical decision support software that analyzes tumor genetic profiles to identify optimal drug combinations.
- Personal Discovery Process (PDP)
Products and services
- TuMatch Rapid, personalized clinical decision support software that analyzes the genetic and molecular profile of a patient's tumor to identify the most effective therapies and drug combinations for individual cancer patients.
- Personal Discovery Process (PDP) Comprehensive genomics-based drug screening service that engineers a patient's tumor mutations into fruit fly avatars and screens up to 2,000 FDA/NICE-approved drugs to identify personalized drug cocktails targeting the patient's specific tumor network.
- Second Opinion Concierge service providing second opinion consultation for patients seeking additional expert review of their cancer treatment options.
Quantifiable outcome
- Up to 500,000 fruit fly avatars engineered per patient to screen drug combinations
- +4 more outcomes
Companies that use VIVAN Therapeutics
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
VIVAN Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
VIVAN Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- MRC Laboratory of Medical SciencescoreVIVAN Therapeutics and the MRC Laboratory of Medical Sciences announced a partnership to study how KRAS mutations, diabetes, and diet influence chemotherapy responses, utilizing VIVAN's in vivo fruit fly screening platform. The collaboration aims to develop personalized cancer treatment recommendations for patients with Type 2 diabetes or obesity. The initiative is supported by the UK's MRC to advance translational research in personalized oncology.
- Mt. Sinai Medical Center (Icahn School of Medicine)coreVIVAN's Personal Discovery Process was developed in partnership with Mt. Sinai Medical Center / Icahn School of Medicine in New York. The technology underlying PDP was developed by scientists at the Icahn School of Medicine and is backed by decades of academic cancer research. PDP methods are licensed exclusively to My Personal Therapeutics (trading as VIVAN Therapeutics).
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
VIVAN Therapeutics competitors and assessment
Company assessmentDirect peers
- Notable Labs: Notable Labs uses patient-specific functional drug screening (via cell-based models) combined with AI to identify personalized cancer treatments. Direct peer because both companies employ patient-derived biological models + AI to recommend personalized combination therapies for refractory cancers.
- xCures: xCures is an AI-driven precision oncology platform that aggregates patient records and molecular data to identify personalized treatment options for advanced cancer patients. Direct peer because it similarly uses AI/ML to match hard-to-treat cancer patients with non-standard, often off-label drug combinations.
- Strata Oncology: Strata provides molecular-guided precision oncology treatment selection for advanced cancer patients, combining tumor profiling with treatment recommendation software. Direct peer as both deliver clinical decision support for oncologists seeking personalized therapy choices.
Broad incumbents
- Tempus AI: Tempus is a leading AI-powered precision medicine company combining multi-modal data (genomics, imaging, clinical) to support oncologist treatment decisions at scale. Broad incumbent offering overlapping clinical decision support but with vastly larger datasets, established reimbursement, and broader cancer-type coverage.
- Foundation Medicine: Foundation Medicine (Roche subsidiary) provides comprehensive genomic profiling of tumors and associated clinical decision support tools used widely by oncologists. Broad incumbent offering molecular-guided treatment selection with established FDA-cleared tests and payer coverage.
- Caris Life Sciences: Caris offers molecular profiling (MI Profile) and AI-driven precision oncology decision support with multiple service lines across diagnostics and treatment selection. Broad incumbent providing molecular-guided therapy recommendations comparable to VIVAN's TuMatch service.
- Personalis: Personalis provides tumor genomic profiling and immune-based biomarker analysis for cancer treatment selection. Broad incumbent operating in adjacent precision oncology space with overlap in multi-gene tumor characterization for therapy decisions.
- Guardant Health: Guardant Health is a leading liquid biopsy and precision oncology company providing blood-based tumor profiling for treatment selection. Broad incumbent offering genomic-guided clinical decision support with FDA-approved tests and established commercial scale.
Emerging players
- Lantern Pharma: Lantern Pharma uses AI and machine learning to develop and identify oncology drug combinations, particularly focused on drug repurposing for rare and refractory cancers. Emerging player with overlapping AI-oncology approach but focused on drug development rather than patient-specific screening.
- Massive Bio: Massive Bio uses AI to match cancer patients to clinical trials and personalized treatment options, including off-label and combination therapies. Emerging player with overlapping AI-driven personalized oncology matching mission for hard-to-treat cancer patients.
Market position
Strengths4 records
Weaknesses3 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
VIVAN Therapeutics social profiles
Digital presenceVIVAN Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
VIVAN Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
VIVAN Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VIVAN Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VIVAN Therapeutics
What does VIVAN Therapeutics do?
VIVAN Therapeutics delivers personalized cancer treatment recommendations by sequencing a patient's tumor exome, engineering the identified mutations into fruit fly (Drosophila) avatars, and using robotics and AI/ML to screen up to 2,000 FDA/NICE-approved drugs (including non-cancer drugs) across up to 500,000 avatars. The output is a ranked treatment recommendation report delivered to the patient and their oncologist/tumour board for clinical review.
Is VIVAN Therapeutics a public or private company?
VIVAN Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was VIVAN Therapeutics founded?
VIVAN Therapeutics was founded in 2018. It employs 11 to 50 people.
Where is VIVAN Therapeutics based?
VIVAN Therapeutics is headquartered in London, United Kingdom, in the Europe region.
How does VIVAN Therapeutics make money?
One revenue line is on record: personalized Cancer Treatment Recommendations (TuMatch/PDP).
Who are VIVAN Therapeutics's main competitors?
Direct peers on record are Notable Labs, xCures and Strata Oncology. Broad incumbents are Tempus AI, Foundation Medicine, Caris Life Sciences, Personalis and Guardant Health. Emerging players are Lantern Pharma and Massive Bio.
Does VIVAN Therapeutics have an API?
No public API is recorded for VIVAN Therapeutics.
What industry is VIVAN Therapeutics in?
VIVAN Therapeutics's product category is Precision Oncology Services. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.